Table 4

Univariate analysis of enhancer of zeste homolog 2 (EZH2) expression and various clinicopathological parameters in 338 patients with primary hepatocellular carcinoma

VariableTesting cohortValidation cohort
All casesHR (95% CI)p value*All casesHR (95% CI)p Value*
Age (years)0.6270.721
 ≤47.91051.0611.0
 >47.91071.090 (0.770 to 1.542)651.109 (0.628 to 1.959)
Sex0.0450.558
 Male1741.650 (1.012 to 2.688)1091.293 (0.548 to 3.052)
 Female381.0171.0
Hepatitis history0.8100.991
 Yes1641.053 (0.692 to 1.602)1071.004 (0.450 to 2.240)
 No481.0191.0
AFP (ng/ml)0.0000.000
 ≤20671.0561.0
 >201452.262 (1.490 to 3.434)705.305 (2.826 to 9.958)
Liver cirrhosis0.8910.983
 Yes1320.975 (0.682 to 1.395)881.0
 No801.0380.993 (0.539 to 1.831)
Tumour size (cm)0.0000.000
 ≤5591.0761.0
 >51536.295 (3.688 to 10.747)502.839 (1.586 to 5.082)
Tumour multiplicity0.0000.000
 Single1281.0871.0
 Multiple843.480 (2.429 to 4.987)393.672 (2.065 to 6.529)
Differentiation0.0210.102
 Well-moderate1531.0871.0
 Poor-undifferentiated591.534 (1.068 to 2.203)391.630 (0.908 to 2.927)
Stage0.0000.000
 I–II881.0621.0
 III–IV1245.393 (3.525 to 8.252)645.400 (2.526 to 11.542)
Vascular invasion0.0000.000
 Yes1084.923 (3.310 to 7.322)575.362 (2.724 to 10.553)
 No1041.0691.0
Relapse0.0000.000
 Yes1051.907 (1.330 to 2.734)432.860 (1.600 to 5.112)
 No1071.0831.0
EZH20.0010.009
 Negative expression261.0161.0
 Positive expression1863.506 (1.703 to 7.219)1105.451 (1.318 to 22.543)
  • * χ2 test.

  • Mean age.